We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+30.53%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$706M
AUM Growth
+$74.9M
Cap. Flow
+$18.2M
Cap. Flow %
2.57%
Top 10 Hldgs %
71.67%
Holding
75
New
24
Increased
13
Reduced
7
Closed
20

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$40.9M
2
LLY icon
Eli Lilly
LLY
+$20.8M
3
VKTX icon
Viking Therapeutics
VKTX
+$20.3M
4
QURE icon
uniQure
QURE
+$14.1M
5
CDTX
Cidara Therapeutics
CDTX
+$11.4M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$40.4M
2
MRUS
Merus
MRUS
+$27.9M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21.6M
4
BSX icon
Boston Scientific
BSX
+$17.9M
5
ARGX icon
argenx
ARGX
+$11.7M

Sector Composition

Rank Sector Weight
1 Healthcare 84.71%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$23.2B
$119M 16.82%
682,212
-50,000
-7% -$9.12M
ABVX
2
Abivax
ABVX
$11B
$81M 11.48%
600,747
+375,294
+166% +$40.9M
INSM icon
3
PUT
Insmed
INSM
$23.2B
$73.1M 10.36%
+420,000
New +$76.6M
ARGX icon
4
argenx
ARGX
$57.4B
$54.4M 7.71%
64,699
-13,612
-17% -$11.7M
LLY icon
5
Eli Lilly
LLY
$1.07T
$54.3M 7.69%
50,500
+21,800
+76% +$20.8M
VKTX icon
6
Viking Therapeutics
VKTX
$4.04B
$25.3M 3.59%
719,365
+573,186
+392% +$20.3M
TRVI icon
7
Trevi Therapeutics
TRVI
$2.49B
$25.2M 3.57%
2,013,602
+13,900
+0.7% +$161K
SLNO
8
DELISTED
Soleno Therapeutics
SLNO
$24.7M 3.5%
533,698
-138,478
-21% -$7.59M
UGL icon
9
ProShares Ultra Gold
UGL
$650M
$24.5M 3.48%
442,119
-95,253
-18% -$4.99M
QURE icon
10
uniQure
QURE
$2.68B
$24.5M 3.47%
1,023,539
+364,700
+55% +$14.1M
NAMS icon
11
NewAmsterdam Pharma
NAMS
$3.47B
$17.7M 2.5%
503,936
+309,098
+159% +$11.2M
AZN icon
12
AstraZeneca
AZN
$263B
$17.5M 2.48%
95,376
– –
CDTX
13
DELISTED
Cidara Therapeutics
CDTX
$15.6M 2.22%
+70,824
New +$11.4M
EYPT icon
14
EyePoint Inc
EYPT
$1.02B
$14M 1.99%
767,098
+138,731
+22% +$1.97M
IONS icon
15
Ionis Pharmaceuticals
IONS
$9.35B
$11.4M 1.62%
144,376
+84,200
+140% +$6.34M
DNTH icon
16
Dianthus Therapeutics
DNTH
$5.68B
$8.45M 1.2%
205,090
+96,367
+89% +$3.74M
RVMD icon
17
Revolution Medicines
RVMD
$40.2B
$8.3M 1.18%
104,190
– –
DGX icon
18
Quest Diagnostics
DGX
$25.1B
$7.08M 1%
40,817
-40,900
-50% -$7.45M
ALNY icon
19
Alnylam Pharmaceuticals
ALNY
$36.3B
$6.92M 0.98%
17,400
-17,170
-50% -$7.6M
VTYX
20
DELISTED
Ventyx Biosciences
VTYX
$6.28M 0.89%
+695,982
New +$5.2M
PVLA
21
Palvella Therapeutics
PVLA
$1.98B
$6.2M 0.88%
+59,200
New +$5.05M
UGL icon
22
PUT
ProShares Ultra Gold
UGL
$650M
$5.55M 0.79%
+100,000
New +$5.24M
MLYS icon
23
Mineralys Therapeutics
MLYS
$2.35B
$5M 0.71%
137,800
+81,200
+143% +$3.26M
SION
24
Sionna Therapeutics
SION
$2.06B
$4.93M 0.7%
+119,741
New +$4.54M
PALI icon
25
Palisade Bio
PALI
$339M
$4.68M 0.66%
+1,992,367
New +$3.83M
1
2 3

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
HSG
Helen Stephens Group Fort Worth, Texas $501M AUM 16.23% 1-Year Est. Return

Artia Global Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Artia Global Partners held 75 positions worth $706M, up 12% from $631M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Artia Global Partners's Q4 2025 filing shows 24 new, 13 increased, 7 reduced and 20 closed positions. Its largest new stake was Cidara Therapeutics: 70,824 shares worth $15.6M. The largest sale was Verona Pharma, an estimated $40.4M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier, followed by Financials.

  • Artia Global Partners's largest Q4 2025 buy was Cidara Therapeutics: 70,824 shares worth $15.6M.
  • Artia Global Partners added most to Abivax in Q4 2025, an estimated $40.9M increase.
  • Artia Global Partners's biggest Q4 2025 reduction was argenx, cutting an estimated $11.7M.
  • Artia Global Partners fully exited Verona Pharma in Q4 2025, selling an estimated $40.4M.
  • Artia Global Partners's ten largest holdings make up 72% of its $706M portfolio in Q4 2025.
  • Artia Global Partners opened 24 new positions and closed 20 in Q4 2025.
  • Artia Global Partners's portfolio value rose 12% quarter-over-quarter to $706M.

Based on Artia Global Partners's 13F filing for Q4 2025, filed 17 Feb 2026.